Continue reading this on our app for a better experience

Open in App
Floating Button
Home News Covid-19

Singapore eDevelopment shares surged as high as 79% following news of its success against Covid-19 with its biotechnologies

Felicia Tan
Felicia Tan • 1 min read
Singapore eDevelopment shares surged as high as 79% following news of its success against Covid-19 with its biotechnologies
Shares in Singapore eDevelopment (SeD) surged as high as 79% to 10 cents following its announcement of its in-vitro success against Covid-19 with its biotechnologies.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (June 24): Shares in Singapore eDevelopment (SeD) surged as high as 79% to 10 cents following its announcement of its in-vitro success against Covid-19 with its biotechnologies.

Earlier today, SeD’s wholly-owned subsidiary Impact Biomedical said it has successfully proved in-vitro success of Equivir, an over-the-counter (OTC) medication, and 3F Biofragrance, a surface disinfectant, against Covid-19.

Currently, no known COVID-19 vaccines or preventive medication have been developed.

The tests were conducted and confirmed by an independent university laboratory, which was contracted to challenge the compounds against the SARS-CoV-2 virus in their advanced Biosafety Level 3 containment facilities.

On June 11, Impact Biomedical, together with Global Research and Discovery Group Sciences (GRDG), had their Covid-19 research published in the peer-reviewed scientific journal Molecules.

The research was conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. (Vilotos).


See: Singapore eDevelopment subsidiary discovers potential medicines to inhibit Covid-19 in peer-reviewed scientific journal

Shares in Singapore eDevelopment closed 3.6 cents higher, or 64.3% up, at 9.2 cents on Wednesday, following the announcement.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

Get the latest news updates in your mailbox
Never miss out on important financial news and get daily updates today
×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.